A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata

Learn more about:
Related Clinical Trial
A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata Modified SALT Score for Alopecia Areata Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Comparative Study Examining the Effectiveness in Use of a DERMOJET and a Normal Syringe Treatment for Patients With Hair Loss – Alopecia Areata TREg Activation in the Treatment of the PELADE (Alopecia Areata) The Effectiveness of Mindfulness Based Cognitive Group Therapy for Social Anxiety Symptoms in People Living With Alopecia Areata Response of Topical Capsaicin in Alopecia Areata Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata. Jaktinib Dihydrochloride Monohydrate in Severe Alopecia Areata Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata Follicular Revival in Treatment-resistant Alopecia Areata: Evaluating Use of Micro-needling Cryotherapy Versus Steroids In Alopecia Areata:Trichoscopic Evaluation Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata The Efficiency Of The Methotrexate At Patients Affected By Grave Pelade Stem Cell Educator Therapy in Alopecia Areata Comparative Study for Treatment of Alopecia Areata Using Carboxytherapy and Intralesional Steroids The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata Vytorin in the Treatment of Alopecia Areata Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata The Efficacy and Safety of Different Concentrations of Localized Injections of Steroids in the Treatment of Alopecia Areata Transepidermal Delivery of Triamcinolone Acetonide or Platelet Rich Plasma Using Either Fractional Carbon Dioxide Laser or Microneedling in Treatment of Alopecia Areata A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata Efficacy and Safety of LH-8 in Paediatric Alopecia Areata Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata Intralesional Steroids in the Treatment of Alopecia Areata A Phase II Study in Patients With Alopecia Areata Topical Crisaborole in Patients With Alopecia Areata Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata Efficacy of Fractional CO2 Laser as a Mono- or Adjuvant Therapy for Alopecia Areata Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5% Efficacy Study of a Cosmetic Lotion in the Treatment of Alopecia Areata in Males and Females Excimer Light for Alopecia Areata Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata Safety and Efficacy Study of SHAPE Gel in Alopecia Areata Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata Topical Garlic Concentrate for Alopecia Areata in Children Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata Aldara for the Treatment of Extensive Alopecia Areata A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata Topical Calcipotriol Versus Narrowband Ultraviolet B in Treatment of Alopecia Areata LEO 124249 Ointment in the Treatment of Alopecia Areata Childhood Alopecia Areata Study Using the 308-nm Excimer Laser Alefacept in Patients With Severe Scalp Alopecia Areata Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia Areata

Brief Title

A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata

Official Title

A Randomized Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata

Brief Summary

      The purpose of this study is to determine if receiving sub-cutaneous injections of a
      medication called abatacept causes regrowth of hair in people with alopecia areata.

      Among patients with alopecia areata, patients with worse disease are unlikely to have
      satisfactory outcomes with current therapies. Our hypothesis is that Abatacept will be
      effective therapy in moderate to severe alopecia areata by blocking re-activation of a
      special type of immunecell call a memory T-Cell (CD8+NKG2D+)thereby blocking the inflammatory
      response underlying alopecia areata.
    

Detailed Description

      Alopecia areata (AA) is a common disease of the immune system, known as an "autoimmune"
      disease. In the disease, the immune system mistaken destroys the hair follicle, causing hair
      to fall out. Despite many people having this disease, research into its cause and into new,
      better ways to treat AA has lagged far behind other similar diseases of the immune system.
      Currently, there are no Federal Drug Administration approved drugs for AA. Abatacept (made by
      Bristol-Myers Squibb) is a safe intervention known to effectively treat rheumatoid
      arthritis,another "autoimmune" disease, by fighting inflammation. There are some genetic and
      chemical similarities between those with active rheumatoid arthritis and AA, suggesting that
      treatment with the same drug is likely to be effective.

      In mice specially designed for testing drugs for the treatment of human alopecia, this
      medication worked to prevent the disease AA from starting. To test Abatacept, we are going to
      treat 60 patients with moderate to severe AA for 6 months. To make the study results
      meaningful, there will be a control or "placebo" group that does not receive the study drug.
      Patients will be randomly assigned to either receive the real or the inactive medication, and
      neither the patient nor the doctor will know which it is. The effectiveness of the medication
      will be measured by changes in hair re-growth as determined by physical exam and photography,
      as well as by patient and physician scoring. Patients will be followed for another 6 months
      off of the drug to see if the effects of treatment last and if there is delayed response.
      Small scalp biopsies and peripheral blood will be taken at the beginning of the study before
      treatment and then after 4,12 and 24 weeks. The chemical analysis of these skin samples and
      blood will help us to understand how the disease happens, how the treatment works, and even
      guide us to better treatments in the future.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

SALT Score (Severity of Alopecia Tool)

Secondary Outcome

 Efficacy

Condition

Alopecia Areata

Intervention

Abatacept

Study Arms / Comparison Groups

 abatacept
Description:  

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

0

Start Date

August 2013

Completion Date

August 2016

Primary Completion Date

August 2016

Eligibility Criteria

        Inclusion Criteria:

          -  Signed Written Informed Consent

          -  Must be between 18 and 75 years of age.

          -  Must have a diagnosis of moderate to severe AA - defined as the presence of equal to
             or more than 40% and equal to or less than 95% total scalp hair loss at baseline as
             measured using the SALT score.

          -  Duration of hair loss must be between 3 to 12 months.

          -  There may be no evidence of regrowth present at baseline.

          -  Subjects may be naïve to treatment or unresponsive to intralesional (IL) steroids or
             other treatments for AA.

          -  Must be willing to avoid live vaccines while on the study medication, and within 3
             months of its discontinuation.

          -  Women of childbearing potential must use highly effective methods of birth control
             [for up to 12 weeks after the last dose of investigational product] to minimize the
             risk of pregnancy].

          -  Women of childbearing potential must follow instructions for birth control for the
             entire duration of the study including a minimum of 90 days after dosing has been
             completed.

          -  Women must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L
             or equivalent units of HCG) within 24 hours prior to the start of investigational
             product.

          -  Women must not be breastfeeding

          -  Sexually active fertile men must use highly effective birth control if their partners
             are women of childbearing potential.

          -  Men that are sexually active with women of childbearing potential must follow
             instructions for birth control for the entire duration of the study and a minimum of
             90 days after dosing has been completed.

        Exclusion Criteria:

          -  Women of childbearing potential who are unwilling or unable to use an acceptable
             method to avoid pregnancy for the entire study period and for up to 10 weeks after the
             last dose of study drug.

          -  Women of childbearing potential using a prohibited contraceptive method.

          -  Women who are pregnant or breastfeeding.

          -  Women with a positive pregnancy test on enrollment or before administration of
             abatacept.

          -  Sexually active fertile men not using effective birth control if their partners are
             women of childbearing potential.

          -  Patients with alopecia totalis/universalis

          -  Patients with a history of or active skin disease on the scalp such as psoriasis or
             seborrheic dermatitis.

          -  Patients in whom the diagnosis of alopecia areata is in question.

          -  Patients with active medical conditions or malignancies (except adequately treated
             basal or squamous cell carcinoma) that in the opinion of the investigator would
             increase the risks associated with study participation, including patients with a
             history of recurrent infections.

          -  Patients with COPD

          -  Patients known to be HIV or hepatitis B or C positive.

          -  Patients with history or evidence of hematopoietic abnormality.

          -  Patients with history of immunosuppression or history of recurrent serious infections.

          -  Patients unwilling or unable to discontinue treatments known to affect hair regrowth
             in AA

          -  Patients taking TNF antagonists or other biological therapy such as anakinra.

          -  Patients known to be HIV or hepatitis B or C positive.

          -  Patients with evidence of infection or active/untreated skin cancer.

          -  Patients who have been treated with intralesional steroids, systemic steroids,
             anthralin, squaric acid, DPCP (diphenylcycloprophenone), protopic, minoxidil or other
             medication which in the opinion of the investigator may affect hair regrowth within
             one month of the baseline visit.

          -  Subjects who are impaired, incapacitated, or incapable of completing study-related
             assessments.

          -  Subjects with current symptoms of severe, progressive, or uncontrolled renal, hepatic,
             hematologic, gastrointestinal, pulmonary, cardiac, neurologic, or cerebral disease,
             which, in the opinion of the investigator, might place a subject at unacceptable risk
             for participation in the study.

          -  Female subjects who have had a breast cancer screening that is suspicious for
             malignancy and in whom the possibility of malignancy cannot be reasonably excluded by
             additional clinical, laboratory, or other diagnostic evaluations.

          -  Subjects with a history of cancer in the last 5 years, other than non-melanoma skin
             cell cancers cured by local resection or carcinoma in situ.

        Existing non-melanoma skin cell cancers should be removed, the lesion site healed, and
        residual cancer ruled out before administration of the study drug.

          -  Subjects who currently abuse drugs or alcohol.

          -  Subjects with evidence (as assessed by the investigator) of active or latent bacterial
             or viral infections at the time of potential enrollment, including subjects with
             evidence of human immunodeficiency virus (HIV) detected during screening.

          -  Subjects with herpes zoster or cytomegalovirus (CMV) that resolved less than 2 months
             before the informed consent document was signed.

          -  Subjects who have received any live vaccines within 3 months of the anticipated first
             dose of study medication.

          -  Subjects with any serious bacterial infection within the last 3 months, unless treated
             and resolved with antibiotics, or any chronic bacterial infection (e.g., chronic
             pyelonephritis, osteomyelitis, or bronchiectasis).

          -  Subjects at risk for tuberculosis (TB). Specifically excluded from this study will be
             subjects with a history of active TB within the last 3 years, even if it was treated;
             a history of active TB greater than 3 years ago, unless there is documentation that
             the prior anti-TB treatment was appropriate in duration and type; current clinical,
             radiographic, or laboratory evidence of active TB; and latent TB that was not
             successfully treated (≥ 4 weeks).

          -  Subjects must not be positive for HIV, Hepatitis B or C.

          -  Subjects who are positive for hepatitis C antibody

          -  Subjects who have at any time received treatment with any investigational drug within
             28 days

          -  Any concomitant biologic Disease Modifying Anti-Rheumatic Drugs (DMARDS), such as
             anakinra.

          -  Subjects who have been treated with intralesional steroids, systemic steroids,
             anthralin, squaric acid, DPCP (diphenylcycloprophenone), protopic, minoxidil or other
             medication which in the opinion of the investigator may affect hair regrowth within
             one month of the baseline visit.

        OTHER EXCLUSION CRITERIA

          -  Prisoners or subjects who are involuntarily incarcerated.

          -  Subjects who are compulsorily detained for treatment of either a psychiatric or
             physical (e.g., infectious disease) illness.
      

Gender

All

Ages

18 Years - 75 Years

Accepts Healthy Volunteers

No

Contacts

Julian Mackay-Wiggan, MD, MS, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT01917058

Organization ID

AAAL0950


Responsible Party

Principal Investigator

Study Sponsor

Columbia University


Study Sponsor

Julian Mackay-Wiggan, MD, MS, Principal Investigator, Columbia University


Verification Date

July 2014